NO20073876L - Pyrazolopyrimidinderivater som mGluR2-antagonister - Google Patents
Pyrazolopyrimidinderivater som mGluR2-antagonisterInfo
- Publication number
- NO20073876L NO20073876L NO20073876A NO20073876A NO20073876L NO 20073876 L NO20073876 L NO 20073876L NO 20073876 A NO20073876 A NO 20073876A NO 20073876 A NO20073876 A NO 20073876A NO 20073876 L NO20073876 L NO 20073876L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazolopyrimidine derivatives
- derivatives
- mglur2 antagonists
- preparation
- treatment
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05101027 | 2005-02-11 | ||
| PCT/EP2006/000940 WO2006084634A1 (fr) | 2005-02-11 | 2006-02-03 | Derives de pyrazolopyrimidine en tant qu’antagonistes de mglur2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073876L true NO20073876L (no) | 2007-09-10 |
Family
ID=36090752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073876A NO20073876L (no) | 2005-02-11 | 2007-07-24 | Pyrazolopyrimidinderivater som mGluR2-antagonister |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7361659B2 (fr) |
| EP (1) | EP1851225B1 (fr) |
| JP (1) | JP4708438B2 (fr) |
| KR (1) | KR100968291B1 (fr) |
| CN (1) | CN101115755B (fr) |
| AR (1) | AR052568A1 (fr) |
| AT (1) | ATE512966T1 (fr) |
| AU (1) | AU2006212457B2 (fr) |
| BR (1) | BRPI0607927A2 (fr) |
| CA (1) | CA2597608C (fr) |
| ES (1) | ES2365406T3 (fr) |
| IL (1) | IL184712A (fr) |
| MX (1) | MX2007009106A (fr) |
| NO (1) | NO20073876L (fr) |
| RU (1) | RU2402553C2 (fr) |
| TW (1) | TW200716120A (fr) |
| WO (1) | WO2006084634A1 (fr) |
| ZA (1) | ZA200706353B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085398A1 (fr) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament |
| WO2009110901A1 (fr) * | 2008-03-06 | 2009-09-11 | Sanofi-Aventis | Dihydro-, trihydro- et tétrahydro- cycloalkyloxazolopyrimidinones substituées, préparation et utilisation de celles-ci en tant que modulateurs allostériques de mglur |
| US8207181B2 (en) | 2008-03-06 | 2012-06-26 | Sanofi | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof |
| US20130137865A1 (en) | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| EP2666775A1 (fr) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Pyrazoloquinazolinones et pyrroloquinazolinones substitués en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate du groupe II |
| CN104736140A (zh) | 2012-10-23 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 用于治疗自闭症的mGlu2/3拮抗剂 |
| JP2017513844A (ja) | 2014-04-23 | 2017-06-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト |
| JOP20150179B1 (ar) * | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| EP3000814A1 (fr) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Pyrazoloquinazolinones et pyrroloquinazolinones substitués en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate du groupe II |
| EP4406616A3 (fr) | 2014-11-06 | 2024-11-06 | Bial-R&D Investments, S.A. | Pyrazolo(1,5-a)pyrimidines substituees et leur utilisation dans le traitement de troubles medicaux |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| EP3226915B1 (fr) | 2014-12-03 | 2019-02-20 | Janssen Pharmaceutica NV | Ligands pet mglur2 radiomarqués |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| JP6929285B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| RS60981B1 (sr) | 2015-12-18 | 2020-11-30 | Janssen Pharmaceutica Nv | Radiooznačeni mglur2/3 pet ligandi |
| CA3020305A1 (fr) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Composes imidazo [1,5-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles medicaux |
| EP3440081A4 (fr) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | Composés pyrrolo[1,2-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles médicaux |
| AU2017246455B2 (en) * | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR102530515B1 (ko) | 2016-05-05 | 2023-05-09 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도 |
| WO2017192931A1 (fr) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | Imidazo[1,2-a]pyridines substituées, imidazo[1,2-a]pyrazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux |
| EP3566749A4 (fr) * | 2017-01-09 | 2020-09-23 | Medshine Discovery Inc. | Dérivé thiazole et utilisations de ce dernier |
| WO2019103070A1 (fr) | 2017-11-24 | 2019-05-31 | 大日本住友製薬株式会社 | DÉRIVÉ DE 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE ET SON APPLICATION MÉDICALE |
| US11964969B2 (en) | 2018-07-06 | 2024-04-23 | Phaeno Therapeutics Co., Ltd | Crystal forms of thiazole compound and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713673B2 (en) | 1996-02-07 | 1999-12-09 | Neurocrine Biosciences Inc. | Pyrazolopyrimidines as crf receptor antagonists |
| ATE214704T1 (de) | 1997-07-18 | 2002-04-15 | Hoffmann La Roche | 5h-thiazolo(3,2-a)pyrimidinderivate |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| CA2442557C (fr) * | 2001-04-12 | 2008-12-23 | F. Hoffmann-La Roche Ag | Derives dihydro-benzo¬b|¬1,4|diazepin-2-one utilises comme antagonistes de mglur2(ii) |
| DE602004012083T2 (de) * | 2003-04-15 | 2009-04-23 | Astrazeneca Ab | Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| BRPI0512330A (pt) * | 2004-06-21 | 2008-02-26 | Hoffmann La Roche | derivados de pirazol-pirimidina |
-
2006
- 2006-02-03 BR BRPI0607927-0A patent/BRPI0607927A2/pt not_active IP Right Cessation
- 2006-02-03 EP EP06706609A patent/EP1851225B1/fr not_active Expired - Lifetime
- 2006-02-03 JP JP2007554484A patent/JP4708438B2/ja not_active Expired - Fee Related
- 2006-02-03 WO PCT/EP2006/000940 patent/WO2006084634A1/fr not_active Ceased
- 2006-02-03 CA CA2597608A patent/CA2597608C/fr not_active Expired - Fee Related
- 2006-02-03 ES ES06706609T patent/ES2365406T3/es not_active Expired - Lifetime
- 2006-02-03 MX MX2007009106A patent/MX2007009106A/es active IP Right Grant
- 2006-02-03 RU RU2007128624/04A patent/RU2402553C2/ru not_active IP Right Cessation
- 2006-02-03 AT AT06706609T patent/ATE512966T1/de active
- 2006-02-03 KR KR1020077018345A patent/KR100968291B1/ko not_active Expired - Fee Related
- 2006-02-03 AU AU2006212457A patent/AU2006212457B2/en not_active Ceased
- 2006-02-03 CN CN2006800046579A patent/CN101115755B/zh not_active Expired - Fee Related
- 2006-02-06 US US11/348,105 patent/US7361659B2/en not_active Expired - Fee Related
- 2006-02-06 AR ARP060100412A patent/AR052568A1/es not_active Application Discontinuation
- 2006-02-08 TW TW095104260A patent/TW200716120A/zh unknown
-
2007
- 2007-07-19 IL IL184712A patent/IL184712A/en not_active IP Right Cessation
- 2007-07-24 NO NO20073876A patent/NO20073876L/no not_active Application Discontinuation
- 2007-07-31 ZA ZA200706353A patent/ZA200706353B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101115755B (zh) | 2013-01-16 |
| IL184712A0 (en) | 2007-12-03 |
| AU2006212457A1 (en) | 2006-08-17 |
| JP2008530042A (ja) | 2008-08-07 |
| BRPI0607927A2 (pt) | 2009-10-20 |
| ES2365406T3 (es) | 2011-10-04 |
| ATE512966T1 (de) | 2011-07-15 |
| MX2007009106A (es) | 2007-09-11 |
| TW200716120A (en) | 2007-05-01 |
| IL184712A (en) | 2013-05-30 |
| RU2007128624A (ru) | 2009-03-20 |
| EP1851225B1 (fr) | 2011-06-15 |
| WO2006084634A1 (fr) | 2006-08-17 |
| US7361659B2 (en) | 2008-04-22 |
| EP1851225A1 (fr) | 2007-11-07 |
| AR052568A1 (es) | 2007-03-21 |
| CA2597608C (fr) | 2013-12-24 |
| KR100968291B1 (ko) | 2010-07-07 |
| US20060183756A1 (en) | 2006-08-17 |
| KR20070104592A (ko) | 2007-10-26 |
| JP4708438B2 (ja) | 2011-06-22 |
| ZA200706353B (en) | 2009-09-30 |
| CN101115755A (zh) | 2008-01-30 |
| AU2006212457B2 (en) | 2011-04-14 |
| CA2597608A1 (fr) | 2006-08-17 |
| RU2402553C2 (ru) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073876L (no) | Pyrazolopyrimidinderivater som mGluR2-antagonister | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20074258L (no) | Pyridin-2-karboksamidderivater som MGLUR5 antagonister | |
| NO20092342L (no) | Azaspiroderivativater | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20045301L (no) | Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav. | |
| NO20083919L (no) | Pyridin- og pyrimidinderivater som mGluR2-antagonister | |
| NO20070339L (no) | 1-aza-bicyklo[3 3.1]nonaner | |
| NO20072784L (no) | Pyridenkarboksamidderivater for anvendelse som anticancer midler | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20070199L (no) | Substituerte kinazoloner som anti-kreftmidler | |
| NO20071703L (no) | Kinazolinderivater | |
| NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
| NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
| WO2009010871A3 (fr) | Nouveaux dérivés hétéroaryle servant d'antagonistes du récepteur a3 de l'adénosine | |
| NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
| NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| NO20076060L (no) | Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister | |
| NO20062923L (no) | Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| NO20091766L (no) | Spiro-piperidinderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |